<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04530201</url>
  </required_header>
  <id_info>
    <org_study_id>BE3002020000101</org_study_id>
    <nct_id>NCT04530201</nct_id>
  </id_info>
  <brief_title>CASUS: Validation for Detection of Precursor Lesions</brief_title>
  <acronym>CASUS-WP4</acronym>
  <official_title>Developing a Complete Cervical Cancer Screening Solution Based on First-void Urine Self-sampling: Validation for Detection of Precursor Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universiteit Antwerpen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novosanis NV</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Self-screen B.V.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universiteit Antwerpen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the overall CASUS project is to develop the first fully molecular integrated&#xD;
      cervical cancer screening approach, based on first-void urine as an easily accessible and&#xD;
      non-invasive source of biomarkers. In contrast to current screening modalities, the CASUS&#xD;
      approach will identify women with clinically relevant disease in need of treatment using only&#xD;
      a single sample that can be collected at home (one-step triage).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CASUS work package 4 (WP4):&#xD;
&#xD;
      The main aim of this study is to validate the HPV-Risk assay (Self-screen, The Netherlands)&#xD;
      followed by multiplex methylation specific quantitative PCR (qMSP, VU University Medical&#xD;
      Center, The Netherlands) on first-void urine (Colli-Pee Small Volumes (10 mL) device,&#xD;
      Novosanis, Belgium) of HPV positive women for detection of clinically relevant precursor&#xD;
      lesions by sampling a cohort of women referred for colposcopy. The number of women in this&#xD;
      cohort will allow us to clinically validate the use of the HPV-Risk/qMSP assay in DNA&#xD;
      extracts of first-void samples after optimization of sample volume, internal process control,&#xD;
      and DNA extraction method (Centre for the Evaluation of Vaccination, University of Antwerp,&#xD;
      Belgium).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HPV DNA (HPV16, HPV18, other high-risk HPV (HPV31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66, -67, and -68)) measured using the HPV-risk assay (Self-Screen BV).</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Analytical test results:&#xD;
HPV DNA (HPV16, HPV18, other high-risk HPV (HPV31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66, -67, and -68)) concentrations [cycle threshold values] in first-void urine samples from all study participants.&#xD;
Clinical test accuracy:&#xD;
HPV DNA (HPV16, HPV18, other high-risk HPV (HPV31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66, -67, and -68)) test outcomes [positive, negative] in first-void urine samples from all study participants compared to the gold standard reference test for cervical cancer screening; i.e. histology [Cervical Intraepithelial Neoplasia grade 0-3+].</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Methylation ratio of a host cell gene marker panel (PreCursor-U+) measured using quantitative methylation specific PCR (qMSP).</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Analytical test results:&#xD;
Methylation levels of a host cell gene marker panel (PreCursor-U+) reported in a methylation ratio [(2^-deltaCT *100) with CT being cycle threshold values] in first-void urine samples from all study participants.&#xD;
Clinical test accuracy:&#xD;
Methylation panel (PreCursor-U+) test outcomes [positive, negative] in first-void urine samples from all study participants compared to the gold standard reference test for cervical cancer screening; i.e. histology [Cervical Intraepithelial Neoplasia grade 0-3+].</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Human DNA (GAPDH)</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Human DNA (GAPDH) concentrations [cycle threshold values] in first-void urine samples from all study participants measured by quantitative PCR (qPCR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Internal control DNA (IC DNA)</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Internal control DNA (IC DNA) concentrations [cycle threshold values] in first-void urine samples from all study participants measured by quantitative PCR (qPCR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Human DNA (Beta-globin)</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Human DNA (Beta-globin) concentrations [cycle threshold values] in first-void urine samples from all study participants measured using the HPV-risk assay (Self-Screen BV).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Human DNA reference gene (ACTB)</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Human DNA reference gene (ACTB) concentrations [cycle threshold values] in first-void urine samples from all study participants measured by quantitative methylation specific PCR (qMSP).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Cervical Intraepithelial Neoplasia</condition>
  <condition>Human Papilloma Virus</condition>
  <condition>HPV-Related Cervical Carcinoma</condition>
  <condition>Urine</condition>
  <arm_group>
    <arm_group_label>Sample collection</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Women will self-collect two first-void urine samples at home, the day prior to colposcopy. During the colposcopy visit, the clinician will collect an additional cervical smear. Colposcopy and histology results (when available) will be used as reference test.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Colli-Pee Small Volumes (10 mL) device</intervention_name>
    <description>Women will self-collect two first-void urine samples at home the day prior to colposcopy using the new generation Colli-Pee Small Volumes (10 mL) device (Novosanis, Belgium). The collector tube will be prefilled with a non-toxic nucleic acid preservative including an internal process control.</description>
    <arm_group_label>Sample collection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  25 years until 64 years old&#xD;
&#xD;
          -  Referred to colposcopy due to a single/multiple (probable) high-risk HPV infection&#xD;
             and/or abnormal cervical squamous intraepithelial/glandular lesion.&#xD;
&#xD;
          -  Gives informed consent to the research team at the clinical study site to contact&#xD;
             his/her general practitioner and/or gynaecologist to access details of the&#xD;
             participants HPV test results and cervical screening history.&#xD;
&#xD;
          -  Is able to understand the information brochure/what the study is about.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women that underwent hysterectomy&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Treatment for cervical cancer in the last 6 months before participation in the study&#xD;
&#xD;
          -  Participating in an interventional clinical study (where e.g. a medical device, drug,&#xD;
             or vaccine is evaluated) at the same time of participating in this study.&#xD;
             Participation in another observational or low-interventional clinical study at the&#xD;
             same time is allowed.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Van Damme, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universiteit Antwerpen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alex Vorsters, Ir, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Universiteit Antwerpen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Severien Van Keer, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Universiteit Antwerpen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alex Vorsters, Ir, PhD</last_name>
    <phone>03 265 91 30</phone>
    <phone_ext>+32</phone_ext>
    <email>alex.vorsters@uantwerpen.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Severien Van Keer, PhD</last_name>
    <phone>03 265 90 10</phone>
    <phone_ext>+32</phone_ext>
    <email>severien.vankeer@uantwerpen.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vrouwenkliniek - Universitair Ziekenhuis Gent (UZ Gent)</name>
      <address>
        <city>Gent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Weyers, MD, PhD</last_name>
      <phone>09 332 07 58</phone>
      <phone_ext>+32</phone_ext>
      <email>gynobs.studies@uzgent.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Femicare VZW &amp; Departement Verloskunde &amp; Gynaecologie - Regionaal Heilig Hart Ziekenhuis Tienen</name>
      <address>
        <city>Tienen</city>
        <state>Vlaams-Brabant</state>
        <zip>3300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilbert Donders, MD, PhD</last_name>
      <phone>016 80 81 02</phone>
      <phone_ext>+32</phone_ext>
      <email>gilbert.donders@femicare.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gynécologie-obstétrique - CHU de Liège</name>
      <address>
        <city>Liège</city>
        <zip>4030</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Doyen, MD</last_name>
      <phone>04 284 36 33</phone>
      <phone_ext>+32</phone_ext>
      <email>Jean.doyen@chuliege.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 24, 2020</study_first_submitted>
  <study_first_submitted_qc>August 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2020</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universiteit Antwerpen</investigator_affiliation>
    <investigator_full_name>Pierre Van Damme</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Biomarker</keyword>
  <keyword>First-void urine</keyword>
  <keyword>Screening</keyword>
  <keyword>Triage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Papilloma</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

